MedImmune an AstraZeneca (NYSE: AZN) subsidiary has licensed from Crucell (NASDAQ: CRXL) biologicals focused on hospital acquired bacterial infections. Note to Self: look at Methicillin-resistant Staphylococcus aureus market
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment